Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Article
Pharmaceutical Executive
Social Media and Clinical Trial Recruitment
A review of an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Recruitment is one the most important parts of a clinical trial, but when literature is reviewed it seems that not reaching initial recruitment targets within initial timelines is more the rule than the exception. This indicates that current recruitment strategies are shortcoming and need to be reviewed.
This Applied Clinical Trials article describes an online, cross-sectional survey in Belgium that was conducted to systematically assess the opinions of clinical research professionals from different stakeholders about using social media as a targeting recruitment tool.
Click here for more.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Bridging Innovation and Reliability: Why Animal Studies Still Matter in the Age of NAMs
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
Building Promise from Precision
Key Findings of the NIAGARA and HIMALAYA Trials
Pfizer’s Sickle Cell Treatment Fails Phase 3 Study
Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale
Bridging Innovation and Reliability: Why Animal Studies Still Matter in the Age of NAMs
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
Building Promise from Precision
Key Findings of the NIAGARA and HIMALAYA Trials
Pfizer’s Sickle Cell Treatment Fails Phase 3 Study
Sarepta, Arrowhead Advance RNAi Programs with $100 Million Milestone Payment, Stock Sale